|
Molecular properties generated using the CDK |
Classification ![]() |
|
Compound class | Synthetic organic |
Approved drug? | Yes (FDA (2017)) |
IUPAC Name ![]() |
4-nitrooxybutyl (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl]hept-5-enoate |
International Nonproprietary Names ![]() |
|
INN number | INN |
9629 | latanoprostene bunod |
Synonyms ![]() |
BOL-303259-X | NCX-116 | PF-3187207 | Vyzulta® |
Database Links ![]() |
|
CAS Registry No. | 860005-21-6 (source: WHO INN record) |
ChEMBL Ligand | CHEMBL2364612 |
GtoPdb PubChem SID | 340590265 |
PubChem CID | 11156438 |
Search Google for chemical match using the InChIKey | LOVMMUBRQUFEAH-UIEAZXIASA-N |
Search Google for chemicals with the same backbone | LOVMMUBRQUFEAH |
Search PubMed clinical trials | latanoprostene bunod |
Search PubMed titles | latanoprostene bunod |
Search PubMed titles/abstracts | latanoprostene bunod |
Search UniChem for chemical match using the InChIKey | LOVMMUBRQUFEAH-UIEAZXIASA-N |
Search UniChem for chemicals with the same backbone | LOVMMUBRQUFEAH |
Comments |
Latanoprostene bunod is a NO-donating analogue of the prostaglandin F2α agonist latanoprost (isopropyl ester) [3]. This compound benefits from the additive hypotensive actions of both the prostaglandin agonist and NO. Latanoprostene bunod is the first NO-donating prostaglandin analogue to be granted FDA marketing approval [2,4]. |